Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405026 · ClinicalTrials.gov registry record
Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients
A clinical trial of Asthma and HIV, sponsored by Duke University.
- Completed
- Registry status
- 83
- Enrollment target
- 1
- Study location
NCT02405026 is a study of Asthma and HIV that has completed, run by Duke University. The registered enrollment target is 83 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02405026, a study of Asthma and HIV, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the prevalence and severity of asthma in patients with HIV. To determine the immunological phenotype of HIV-infected patients with asthma.
Study Locations (1)
North Carolina
- Duke Asthma Allergy and Airway Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02405026
The ClinicalTrials.gov registry entry for NCT02405026 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT02405026 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02405026 about?
NCT02405026 is a clinical study titled "Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients". The purpose of this study is to determine the prevalence and severity of asthma in patients with HIV. To determine the immunological phenotype of HIV-infected patients with asthma.
What is the current status of trial NCT02405026?
This trial is currently completed. The enrollment target is 83 participants. The study started on 2014-12. Estimated completion is 2017-07.
What conditions does trial NCT02405026 study?
This clinical trial studies the following conditions: Asthma, HIV.
Who is sponsoring clinical trial NCT02405026?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02405026 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.